Steatotic Liver Disease Is a Dynamic Spectrum: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction:

Steatotic liver disease (SLD) is increasingly recognized not as a collection of separate disorders but as a dynamic spectrum driven by interacting metabolic and alcohol-related factors. Obesity, diabetes, hypertension, dyslipidaemia, and alcohol frequently coexist, collectively accelerating fibrosis progression and liver-related mortality. This review proposes a more practical, dynamic framework for diagnosing and managing SLD.

Why was this review needed?

MASLD, MetALD, and alcohol-related liver disease frequently overlap.

Metabolic risk factors and alcohol act synergistically, rather than independently.

Alcohol consumption and metabolic health change over time, making static disease labels potentially misleading.

Under-reporting of alcohol intake can result in substantial misclassification.

Key Takeaways:

Most patients with SLD have multiple cardiometabolic risk factors, which increase fibrosis and cardiovascular risk regardless of the diagnostic label.

Patients can move between MASLD, MetALD, and alcohol-related disease over time as alcohol exposure and metabolic status change.

Assessment should combine structured alcohol screening such as AUDIT-C, objective biomarkers such as phosphatidylethanol (PEth) when appropriate, and non-invasive fibrosis assessment.

Management should simultaneously address alcohol reduction, weight and metabolic control, cardiovascular risk, and liver fibrosis, requiring multidisciplinary care.

Current MASH drug trials frequently exclude patients with meaningful alcohol consumption, creating an important gap between clinical trial evidence and real-world SLD.

Clinical Impact:

SLD should increasingly be viewed as a continuum rather than a fixed diagnostic category. Clinicians should periodically reassess both alcohol exposure and cardiometabolic risk instead of permanently labeling patients as MASLD, MetALD, or alcohol-related liver disease. Treatment should focus on the patient's dominant and modifiable disease drivers, alongside fibrosis severity.

Bottom Line:

Steatotic liver disease is a dynamic spectrum in which metabolic dysfunction and alcohol frequently coexist and amplify liver injury. Repeated assessment of alcohol exposure, cardiometabolic risk, and fibrosis—not static diagnostic labels—offers a more clinically meaningful approach to personalized SLD management.